Literature DB >> 28043921

MicroRNA-134-3p is a novel potential inhibitor of human ovarian cancer stem cells by targeting RAB27A.

Cui Chang1, Te Liu2, Yongyi Huang3, Wenxing Qin4, Hongtu Yang5, Juan Chen6.   

Abstract

The cluster of microRNAs (miRNAs) in the DLK1-DIO3 genomic imprinted region contains several miRNAs that have a significant regulatory role in tumor proliferation and invasion. One of these miRNAs is miR-134-3p, and its expression changes significantly in human ovarian cancer stem cells (OCSCs) and in CD44-/CD133- ovarian cancer. The results of a luciferase assay showed that miR-134-3p silenced RAB27A by binding to the 3'-UTR of RAB27A mRNA. Overexpression of miR-134-3p in human OCSCs can not only inhibit the expression of RAB27A but also can effectively downregulate the expression of some tumor proliferation and invasion genes. Overexpression of miR-134-3p can not only inhibit the in vitro proliferation and cell cycle progression of human OCSCs but also can decrease the tumorigenicity in nude mice.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DLK1-DIO3 microRNA cluster; MicroRNA-134-3p (miR-134-3p); Ovarian cancer stem cells (OCSCs); RAB27A

Mesh:

Substances:

Year:  2016        PMID: 28043921     DOI: 10.1016/j.gene.2016.12.030

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  10 in total

Review 1.  Consequences of Rab GTPase dysfunction in genetic or acquired human diseases.

Authors:  Marcellus J Banworth; Guangpu Li
Journal:  Small GTPases       Date:  2017-12-28

2.  Inhibition of miR-1247 on cell proliferation and invasion in bladder cancer through its downstream target of RAB36.

Authors:  Yudi Zhu; Shaosi Liang; Huafeng Pan; Zhongliang Cheng; Xin Rui
Journal:  J Biosci       Date:  2018-06       Impact factor: 1.826

Review 3.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

Review 4.  The Effect of miRNA Gene Regulation on HIV Disease.

Authors:  Romona Chinniah; Theolan Adimulam; Louansha Nandlal; Thilona Arumugam; Veron Ramsuran
Journal:  Front Genet       Date:  2022-05-04       Impact factor: 4.772

Review 5.  The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.

Authors:  Xiyin Wang; Mircea Ivan; Shannon M Hawkins
Journal:  Gynecol Oncol       Date:  2017-08-31       Impact factor: 5.482

6.  Tumor suppressor miR-211-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma.

Authors:  Jing Quan; Xiang Pan; Tao He; Canbin Lin; Yulin Lai; Peijie Chen; Zeng Zhang; Shangqi Yang; Tao Wang; Yongqing Lai
Journal:  Exp Ther Med       Date:  2018-02-28       Impact factor: 2.447

7.  HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.

Authors:  Carolyn M Klinge; Kellianne M Piell; Christine Schaner Tooley; Eric C Rouchka
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

8.  miR-31-5p from placental and peripheral blood exosomes is a potential biomarker to diagnose preeclampsia.

Authors:  Gang Zou; Qingfang Ji; Zixiang Geng; Xiling Du; Lingyan Jiang; Te Liu
Journal:  Hereditas       Date:  2022-09-19       Impact factor: 2.595

Review 9.  Autophagy and Extracellular Vesicles, Connected to rabGTPase Family, Support Aggressiveness in Cancer Stem Cells.

Authors:  Aude Brunel; Gaëlle Bégaud; Clément Auger; Stéphanie Durand; Serge Battu; Barbara Bessette; Mireille Verdier
Journal:  Cells       Date:  2021-05-27       Impact factor: 6.600

10.  MiRNA-142-3p increases radiosensitivity in human umbilical cord blood mononuclear cells by inhibiting the expression of CD133.

Authors:  Fang Yuan; Lu Liu; Yonghong Lei; Yi Hu
Journal:  Sci Rep       Date:  2018-04-04       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.